We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Fluidigm (FLDM) Licenses CFTR Assay From Baylor Genetics
Read MoreHide Full Article
South San Francisco, CA-based Fluidigm Corporation , a leading player in the analysis of single cells and industrial application of genomics, recently announced that it has entered into a licensing agreement with Baylor Genetics.
Per the agreement, Fluidigm licensed the rights to commercialize the CFTR (cystic fibrosis transmembrane conductance regulator) library prep assay developed by Baylor Genetics for research purposes. This would be used with its proprietary Juno automated microfluidic system. The targeted library prep assay enables accurate identification of variants from each of the 27 exons in the CFTR gene and selected intronic regions. When combined with Fluidigm microfluidics, this solution has the potential to significantly simplify complex labor-intensive laboratory workflows and improve the efficiency of CFTR sequencing. This would invariably improve the efficiency of its Juno automated microfluidic system and help the company to capture a considerable market share.
Next-generation sequencing offers a more comprehensive approach to CFTR genetic analysis by allowing a complete view of the sequence. Targeted sequencing library prep workflows, however, can be very labor-intensive. With the application of Fluidigm automated microfluidics technology, library preparation can be streamlined to provide significant efficiencies.
Over the past one month, Fluidigm has underperformed the broader industry. The stock has shed 7.1%, compared with the industry’s decline of 3.1%.
Fluidigm develops, manufactures and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single cell genomics. The company caters to leading academic institutions, clinical research laboratories and pharmaceuticals, biotechnology and agricultural biotechnology companies worldwide.
Zacks Rank & Key Picks
Currently, Fluidigm has a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Edwards Lifesciences Corp. (EW - Free Report) , Lantheus Holdings, Inc. (LNTH - Free Report) and Align Technology, Inc. (ALGN - Free Report) . Edwards Lifesciences and Align Technology sport a Zacks Rank #1 (Strong Buy), while Lantheus Holdings carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has gained around 3.2% over the last three months.
Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has gained 66.1% over the last six months.
Align Technology has a long-term expected earnings growth rate of 26.6%. The stock has rallied roughly 29.6% over the last three months.
4 Surprising Tech Stocks to Keep an Eye on
Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really take off.
Image: Bigstock
Fluidigm (FLDM) Licenses CFTR Assay From Baylor Genetics
South San Francisco, CA-based Fluidigm Corporation , a leading player in the analysis of single cells and industrial application of genomics, recently announced that it has entered into a licensing agreement with Baylor Genetics.
Per the agreement, Fluidigm licensed the rights to commercialize the CFTR (cystic fibrosis transmembrane conductance regulator) library prep assay developed by Baylor Genetics for research purposes. This would be used with its proprietary Juno automated microfluidic system. The targeted library prep assay enables accurate identification of variants from each of the 27 exons in the CFTR gene and selected intronic regions. When combined with Fluidigm microfluidics, this solution has the potential to significantly simplify complex labor-intensive laboratory workflows and improve the efficiency of CFTR sequencing. This would invariably improve the efficiency of its Juno automated microfluidic system and help the company to capture a considerable market share.
Next-generation sequencing offers a more comprehensive approach to CFTR genetic analysis by allowing a complete view of the sequence. Targeted sequencing library prep workflows, however, can be very labor-intensive. With the application of Fluidigm automated microfluidics technology, library preparation can be streamlined to provide significant efficiencies.
Over the past one month, Fluidigm has underperformed the broader industry. The stock has shed 7.1%, compared with the industry’s decline of 3.1%.
Fluidigm develops, manufactures and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single cell genomics. The company caters to leading academic institutions, clinical research laboratories and pharmaceuticals, biotechnology and agricultural biotechnology companies worldwide.
Zacks Rank & Key Picks
Currently, Fluidigm has a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Edwards Lifesciences Corp. (EW - Free Report) , Lantheus Holdings, Inc. (LNTH - Free Report) and Align Technology, Inc. (ALGN - Free Report) . Edwards Lifesciences and Align Technology sport a Zacks Rank #1 (Strong Buy), while Lantheus Holdings carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has gained around 3.2% over the last three months.
Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has gained 66.1% over the last six months.
Align Technology has a long-term expected earnings growth rate of 26.6%. The stock has rallied roughly 29.6% over the last three months.
4 Surprising Tech Stocks to Keep an Eye on
Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really take off.
See Stocks Now>>